<DOC>
	<DOCNO>NCT02261883</DOCNO>
	<brief_summary>This pilot study aim assess safety treatment effect acute dose IV Remodulin neonates persistent pulmonary hypertension newborn ( PPHN ) .</brief_summary>
	<brief_title>Remodulin Add-on Therapy Treatment Persistent Pulmonary Hypertension Newborn</brief_title>
	<detailed_description>This study enroll subject PPHN show adequate response inhale nitric oxide hypothesis addition intravenous ( IV ) Remodulin reduce rate clinical worsening compare standard care . Additionally , study aim evaluate treatment effect Remodulin good understand dose pharmacokinetics neonatal population .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Parent ( ) guardian provide consent subject participate , per institutional policy At least 2 kg Screening Gestational age ≥ 34 week ≤ 14 day old Screening Diagnosis PPHN , either idiopathic nature associate following : meconium aspiration syndrome ( MAS ) , pneumonia , respiratory distress syndrome ( RDS ) , sepsis , birth hypoxia , perinatal encephalopathy unilateral congenital diaphragmatic hernia ( CDH ) Currently require ventilator support Receiving iNO two OIs 15 great separate least 30 minute receive iNO least 3 hour Echocardiographic evidence pulmonary hypertension elevate right ventricle pressure Dedicated venous access administration study drug ( central line peripherally inserted central venous catheter ) Previous concurrent use phosphodiesterase5 inhibitor ( PDE5i ) , endothelin receptor antagonist ( ERA ) , prostanoid Significant congenital heart disease ( CHD ) detect ECHO ( exclude presence minor defect small secundum atrial septal defect ( ASD ) , minor valvular abnormality , expect transitional finding patent foramen ovale ( PFO ) , patent ductus arteriosus ( PDA ) . Subjects small muscular , restrictive ventricular septal defect ( VSD ) may enrol Clinically significant , untreated active pneumothorax Screening Evidence clinically significant bleed Necrotizing entercolitis ; ≥ Bells stage II Screening Uncontrolled hypotension ; mean systemic pressure ≤ 35 mmHg Screening . Uncontrolled coagulopathy / untreated thrombocytopenia ; define &lt; 50,000 platelet /µL Screening History severe ( Grade 3 4 ) intracranial hemorrhage Currently receive ECMO immediate plan initiate ECMO Expected duration mechanical ventilation le 48 hour Life expectancy less two month lethal chromosomal anomaly Contraindication ECMO Bilateral congenital diaphragmatic hernia Active seizure Screening Currently participate another clinical drug study ( exclude observational registry )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Days</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PPHN</keyword>
</DOC>